Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/S1473-3099(21)00048-7 http://scihub22266oqcxt.onion/10.1016/S1473-3099(21)00048-7 33636148!7906660!33636148     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Lancet+Infect+Dis 2021 ; 21 (9): e290-e295 Nephropedia Template TP {{tp|p=33636148|t=2021. Scaling up COVID-19 rapid antigen tests: promises and challenges |pdf=|usr=}}{{33636148}} gab.com Text Scaling up COVID-19 rapid antigen tests: promises and challenges JO: Lancet Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33636148 #FOAvip WHO recommends a minimum of 80% sensitivity and 97% specificity for antigen-detection rapid diagnostic tests (Ag-RDTs), which can be used for patients with symptoms consistent with COVID-19. However, after the acute phase when viral load decreases, use of Ag-RDTs might lead to high rates of false negatives, suggesting that the tests should be replaced by a combination of molecular and serological tests. When the likelihood of having COVID-19 is low, such as for asymptomatic individuals in low prevalence settings, for travel, return to schools, workplaces, and mass gatherings, Ag-RDTs with high negative predictive values can be used with confidence to rule out infection. For those who test positive in low prevalence settings, the high false positive rate means that mitigation strategies, such as molecular testing to confirm positive results, are needed. Ag-RDTs, when used appropriately, are promising tools for scaling up testing and ensuring that patient management and public health measures can be implemented without delay. Twit Text FOAVip Scaling up COVID-19 rapid antigen tests: promises and challenges ????Lancet Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33636148 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33636148 #FOAvip English Wikipedia <ref>{{Cite pmid|33636148}}</ref> Scaling up COVID-19 rapid antigen tests: promises and challenges #MMPMID33636148 Peeling RW; Olliaro PL; Boeras DI; Fongwen N Lancet Infect Dis 2021[Sep]; 21 (9): e290-e295 PMID33636148show ga WHO recommends a minimum of 80% sensitivity and 97% specificity for antigen-detection rapid diagnostic tests (Ag-RDTs), which can be used for patients with symptoms consistent with COVID-19. However, after the acute phase when viral load decreases, use of Ag-RDTs might lead to high rates of false negatives, suggesting that the tests should be replaced by a combination of molecular and serological tests. When the likelihood of having COVID-19 is low, such as for asymptomatic individuals in low prevalence settings, for travel, return to schools, workplaces, and mass gatherings, Ag-RDTs with high negative predictive values can be used with confidence to rule out infection. For those who test positive in low prevalence settings, the high false positive rate means that mitigation strategies, such as molecular testing to confirm positive results, are needed. Ag-RDTs, when used appropriately, are promising tools for scaling up testing and ensuring that patient management and public health measures can be implemented without delay. |*SARS-CoV-2[MESH] |COVID-19 Testing/*methods/*standards[MESH] |COVID-19/*diagnosis[MESH] |False Negative Reactions[MESH] |False Positive Reactions[MESH] |Humans[MESH] |Predictive Value of Tests[MESH]Scaling up COVID-19 rapid antigen tests: promises and challenges (epmc).pdf DeepDyve Pubget Overpricing